Cite
HARVARD Citation
Konstantinopoulos, P. et al. (2020). Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet oncology. 21 (7), pp. 957-968. [Online].